Alto Neuroscience, Inc. (ANRO)

USD 2.44

(-0.41%)

Total Liabilities Summary of Alto Neuroscience, Inc.

  • Alto Neuroscience, Inc.'s latest annual total liabilities in 2023 was 158.3 Million USD , up 77.35% from previous year.
  • Alto Neuroscience, Inc.'s latest quarterly total liabilities in 2024 Q2 was 17.58 Million USD , up 4.55% from previous quarter.
  • Alto Neuroscience, Inc. reported annual total liabilities of 89.26 Million USD in 2022, up 116.27% from previous year.
  • Alto Neuroscience, Inc. reported annual total liabilities of 41.27 Million USD in 2021, down 0.0% from previous year.
  • Alto Neuroscience, Inc. reported quarterly total liabilities of 16.81 Million USD for 2024 Q1, down -89.38% from previous quarter.
  • Alto Neuroscience, Inc. reported quarterly total liabilities of 158.3 Million USD for 2023 Q4, up 38.45% from previous quarter.

Annual Total Liabilities Chart of Alto Neuroscience, Inc. (2023 - 2021)

Historical Annual Total Liabilities of Alto Neuroscience, Inc. (2023 - 2021)

Year Total Liabilities Total Liabilities Growth
2023 158.3 Million USD 77.35%
2022 89.26 Million USD 116.27%
2021 41.27 Million USD 0.0%

Peer Total Liabilities Comparison of Alto Neuroscience, Inc.

Name Total Liabilities Total Liabilities Difference
ADC Therapeutics SA 503.03 Million USD 68.531%
Annovis Bio, Inc. 17.95 Million USD -781.447%
Biohaven Pharmaceutical Holding Company Ltd. 85.23 Million USD -85.717%
Ginkgo Bioworks Holdings, Inc. 568.19 Million USD 72.14%
Nuvation Bio Inc. 16.36 Million USD -867.486%
Nuvation Bio Inc. 16.36 Million USD -867.486%
Arcus Biosciences, Inc. 633 Million USD 74.992%
Zymeworks Inc. 116.07 Million USD -36.379%